Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGILE THERAPEUTICS INCAGRX · Entity 87994 | Director | June 09, 2022 | June 10, 2022 |
| ANTARES PHARMA, INC.ATRS · Entity 126887 | EVP, Chief Medical Officer | June 13, 2019 | June 14, 2019 |
| Aralez Pharmaceuticals Inc.ARLZ · Entity 165961 | Chief Medical Officer | May 14, 2018 | May 16, 2018 |
| Endo International plcENDP · Entity 124463 | Executive VP, Global R&D | July 15, 2022 | August 17, 2022 |
| MetaVia Inc.MTVA · Entity 7947 | Director | June 08, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGILE THERAPEUTICS INC
Report date June 09, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,066 |
Reported balance
After 2022-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 670 · Balance 2,066 F1: These shares represent restricted stock units that were granted on June 9, 2022, which will vest and be settled in common stock on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. F2: On April 26, 2022, the Issuer completed a one-for-forty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2032-06-08 | Direct | 807 |
Reported balance
After 2022-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-09 · Grant · Acquired 807 · Balance 807 F3: This option was granted on June 9, 2022 and vests in full on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units that were granted on June 9, 2022, which will vest and be settled in common stock on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service.
F2: On April 26, 2022, the Issuer completed a one-for-forty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split.
F3: This option was granted on June 9, 2022 and vests in full on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service.
ANTARES PHARMA, INC.
Report date June 13, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,205 |
Reported balance
After 2019-06-13 transaction · row 1
1 source rowRow 1 · 2019-06-13 · Grant · Acquired 45,205 · Balance 45,205 F1: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.92 · Expires 2029-06-13 | Direct | 90,788 |
Reported balance
After 2019-06-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-13 · Grant · Acquired 90,788 · Balance 90,788 F2: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan. F3: The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant.
F2: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan.
F3: The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date.
Aralez Pharmaceuticals Inc.
Report date May 14, 2018 · Filed May 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, without par valueSEC Table I · non-derivative | Direct | 242,052 |
Reported balance
After 2018-05-14 transaction · row 1
1 source rowRow 1 · 2018-05-14 · Sale · Disposed 9,348 · Balance 242,052 F1: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 27,730 restricted stock units, which were previously granted on May 11, 2017 and which vested on May 11, 2018. F2: This transaction was executed in multiple trades at prices ranging from $0.5206 to $0.5269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 27,730 restricted stock units, which were previously granted on May 11, 2017 and which vested on May 11, 2018.
F2: This transaction was executed in multiple trades at prices ranging from $0.5206 to $0.5269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Endo International plc
Report date July 15, 2022 · Filed August 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 2015 Stock Incentive Plan Restricted Stock Units (RSU)SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-15 transaction · row 1
1 source rowRow 1 · 2022-07-15 · Disposition to issuer · Disposed 280,373 · Balance 0 F1: On July 15, 2022, Dr. Tursi received cash totaling $900,000 in respect of his outstanding RSUs. Upon receipt of this cash payment, the corresponding RSUs were cancelled. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 15, 2022, Dr. Tursi received cash totaling $900,000 in respect of his outstanding RSUs. Upon receipt of this cash payment, the corresponding RSUs were cancelled.
MetaVia Inc.
Report date June 08, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,568 |
Reported balance
After 2026-06-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 17,186 · Balance 20,568 F1: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 8, 2027 or the day immediately prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. F2: The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-11 reverse stock split on December 4, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 8, 2027 or the day immediately prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date.
F2: The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-11 reverse stock split on December 4, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 8, 2026 22:33 UTC | MetaVia Inc. MTVA · Entity 7947 | GrantCommon Stock | 17,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071475 · tm2617186-6_4seq1.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,568 F1 · shares: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 8, 2027 or the day immediately prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. F2 · balance_after: The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-11 reverse stock split on December 4, 2025. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:02 UTC | MetaVia Inc. MTVA · Entity 7947 | GrantCommon Stock | 28,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-064710 · tm2519510-4_4seq1.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,219 F1 · shares: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 30, 2026 or the day immediately prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. Read SEC document |
| June 07, 2024 Filed Jun 7, 2024 23:24 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 5,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-069783 · tm2416741-1_4seq1.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,072 F1 · shares: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's 2022 Equity Incentive Plan, which vests on the earlier of June 7, 2025 or the day immediately prior to the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. F2 · balance_after: The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-8 reverse stock split on December 20, 2023. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 22:12 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 7,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001527710-23-000003 · primary_doc.xml · nonDerivative · entry 2 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,157 F1 · shares: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan. F3 · shares: Vests on the earlier of December 1, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 22:12 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001527710-23-000003 · primary_doc.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan. F2 · shares: 50% of the RSUs immediately vested on the grant date, and the remainder will vest in two equal installments on each subsequent anniversary of the grant date, subject to continuing service. Read SEC document |
| July 15, 2022 Filed Aug 17, 2022 10:31 UTC | Endo International plc ENDP · Entity 124463 | Disposition to issuer2015 Stock Incentive Plan Restricted Stock Units (RSU) | 280,373 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593034-22-000059 · wf-form4_166073227328724.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On July 15, 2022, Dr. Tursi received cash totaling $900,000 in respect of his outstanding RSUs. Upon receipt of this cash payment, the corresponding RSUs were cancelled. F1 · price: On July 15, 2022, Dr. Tursi received cash totaling $900,000 in respect of his outstanding RSUs. Upon receipt of this cash payment, the corresponding RSUs were cancelled. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:45 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 807 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001104659-22-070174 · tm2218213-2_4seq1.xml · derivative · entry 2 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 807 Underlying: Common Stock · 807 shares Expires 2032-06-08 F3 · derivative.exercise_date: This option was granted on June 9, 2022 and vests in full on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:45 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 670 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-070174 · tm2218213-2_4seq1.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,066 F1 · shares: These shares represent restricted stock units that were granted on June 9, 2022, which will vest and be settled in common stock on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. F2 · balance_after: On April 26, 2022, the Issuer completed a one-for-forty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 19:08 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 29,905 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001104659-21-079616 · tm2119345-1_4seq1.xml · derivative · entry 2 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,905 Underlying: Common Stock · 29,905 shares Expires 2031-06-07 F2 · derivative.exercise_date: The option was granted on June 8, 2021 and vests in full on June 8, 2022, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 19:08 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 24,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-079616 · tm2119345-1_4seq1.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,852 F1 · shares: These shares represent restricted stock units that were granted on June 8, 2021, which will vest and be settled in common stock on June 8, 2022, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:22 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,606 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001104659-20-072488 · a4.xml · derivative · entry 2 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,606 Underlying: Common Stock · 22,606 shares Expires 2030-06-08 F2 · derivative.exercise_date: The option was granted on June 9, 2020 and vests in full on June 9, 2021, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:22 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 13,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-072488 · a4.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,342 F1 · shares: These shares represent restricted stock units that were granted on June 9, 2020, which will vest and be settled in common stock on June 9, 2021, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 17:34 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantStock Option (right to buy) · Derivative | 90,788 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001209191-19-037223 · doc4.xml · derivative · entry 2 Tursi James Patrick · CIK 0001527710 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,788 Underlying: Common Stock · 90,788 shares Expires 2029-06-13 F2 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan. F3 · derivative.exercise_date: The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 17:34 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 45,205 | $2.92 | $131,998.60 |
DisclosureSEC source: 0001209191-19-037223 · doc4.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,205 F1 · shares: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 16:32 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-19-034559 · a4.xml · derivative · entry 1 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: The option was granted on June 6, 2019 and vests in full on June 6, 2020, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 18:14 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-18-045755 · doc4.xml · derivative · entry 1 Tursi James Patrick · CIK 0001527710 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-08-06 F1 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. F2 · derivative.exercise_date: The options vest in equal quarterly installments over three years from the date of grant. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 17:01 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionRestricted Stock Units · Derivative | 17,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-039217 · a4.xml · derivative · entry 3 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,949 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 8, 2017, the Reporting Person was granted 17,949 restricted stock units, vesting in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attended at least 75% of the board meetings held during the year of board service. F3 · derivative.expiration_date: On June 8, 2017, the Reporting Person was granted 17,949 restricted stock units, vesting in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attended at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 17:01 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 17,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-039217 · a4.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 17:01 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001104659-18-039217 · a4.xml · derivative · entry 2 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-06-06 F2 · derivative.exercise_date: The option was granted on June 7, 2018 and vests in full on June 7, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| May 14, 2018 Filed May 16, 2018 23:49 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | SaleCommon Shares, without par value | 9,348 | $0.52 | $4,881.53 |
DisclosureSEC source: 0001104659-18-033905 · a4.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,052 F1 · kind: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 27,730 restricted stock units, which were previously granted on May 11, 2017 and which vested on May 11, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.5206 to $0.5269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 21:16 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | SaleCommon Shares, without par value | 5,950 | $1.70 | $10,115.00 |
DisclosureSEC source: 0001104659-18-019364 · a4.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,400 F1 · kind: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 15,789 restricted stock units, which were previously granted on March 17, 2016 and which vested on March 17, 2018. Read SEC document |
| October 02, 2017 Filed Oct 5, 2017 00:32 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | SaleCommon Shares, without par value | 9,960 | $2.50 | $24,917.93 |
DisclosureSEC source: 0001179110-17-013135 · edgar.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,350 F1 · kind: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 29,000 restricted stock units, which vested on October 1, 2017. 7,284 of such restricted stock units were previously granted on October 1, 2015 and 21,716 of such restricted stock units were previously granted on February 12, 2016. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.50 to $2.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 17:04 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantRestricted Stock Units · Derivative | 17,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-038463 · a4.xml · derivative · entry 2 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,949 Underlying: Common Stock · 17,949 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 8, 2017 and vest in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. F3 · derivative.expiration_date: The restricted stock units were granted on June 8, 2017 and vest in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 17:04 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001104659-17-038463 · a4.xml · derivative · entry 1 Tursi James Patrick · CIK 0001527710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The option was granted on June 8, 2017 and vests in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:52 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantEmployee Stock Option (right to buy) · Derivative | 96,121 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001104659-17-032414 · a4.xml · derivative · entry 2 Tursi James Patrick · CIK 0001527710 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,121 Underlying: Common Shares, without par value · 96,121 shares Expires 2027-05-11 F3 · derivative.exercise_date: The option vests as to 25% of the shares on May 11, 2018, and the remainder vests in substantially equal monthly installments over the 36 months immediately following such date, subject to continued employment or service to the Company. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:52 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantCommon Shares, without par value | 83,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-032414 · a4.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,310 F1 · kind: Restricted Stock Units granted pursuant to the Aralez Pharmaceuticals Inc. 2016 Amended and Restated Long-Term Incentive Plan, which vest in substantially equal annual installments over the three years immediately following the date of grant, subject to continued employment or service to the Company. F2 · balance_after: Includes 65,538 shares of Common Stock and 201,772 Restricted Stock Units. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 20:16 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | PurchaseCommon Shares, without par value | 4,750 | $2.11 | $10,022.50 |
DisclosureSEC source: 0001104659-17-017605 · a4.xml · nonDerivative · entry 1 Tursi James Patrick · CIK 0001527710 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,118 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.